Bevacizumab, irinotecan, and radiotherapy versus standard temozolomide and radiotherapy in newly diagnosed, MGMT-non-methylated glioblastoma patients: First results from the randomized multicenter GLARIUS trial.
Ulrich Herrlinger(University of Tübingen), Martin Glas(Essen University Hospital), Roland Goldbrunner(University of Cologne), Ralf Kohnen(Friedrich-Alexander-Universität Erlangen-Nürnberg), Astrid Weyerbrock(University of Freiburg), Christian Braun(Ludwig-Maximilians-Universität München), Claus Belka(LMU Klinikum), Peter Hau(University Hospital Regensburg), Florian Stockhammer(Medizinische Hochschule Hannover), Barbara Leutgeb(Goethe University Frankfurt), Walter Stummer(University of Münster), Niklaus Schaefer(University Hospital of Bern), Joachim P. Steinbach(Goethe University Frankfurt), Florian Ringel(Johannes Gutenberg University Mainz), Franziska Friedrich(Goethe University Frankfurt), Horst Urbach(University of Freiburg)
Cited by 29
Related Papers
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
|The Lancet Oncology|2006|3.4k
EXTENT OF RESECTION AND SURVIVAL IN GLIOBLASTOMA MULTIFORME
|Neurosurgery|2008|1k
Histopathological Findings in Brain Tissue Obtained during Epilepsy Surgery
|New England Journal of Medicine|2017|916